<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143830</url>
  </required_header>
  <id_info>
    <org_study_id>2013-7501</org_study_id>
    <nct_id>NCT02143830</nct_id>
  </id_info>
  <brief_title>HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy</brief_title>
  <acronym>RAFA</acronym>
  <official_title>A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the use of lower doses of busulfan and the
      elimination of cyclosporine will further reduce transplant-related side effects for patients
      with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or
      matched unrelated donors following a preparative regimen of busulfan, fludarabine,
      anti-thymocyte globulin and cyclophosphamide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial proposed is a three arm phase II treatment protocol designed to investigate the
      safety and efficacy of risk-adjusted chemotherapy-based cytoreductive regimen plus a CD34+
      selected T-cell depleted peripheral blood stem cell (PBSC) stem cell transplant for the
      treatment of patients with Fanconi anemia and severe hematologic disease. Candidates for this
      trial will include patients with Fanconi anemia presenting with severe marrow failure
      (transfusion dependent) or myelodysplastic syndrome, or acute myelogenous leukemia for whom
      an allogeneic stem cell transplant is indicated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft Failure or Rejection</measure>
    <time_frame>5 years</time_frame>
    <description>Primary non-engraftment is diagnosed when the patient fails to achieve an ANC &gt;=500/mm3 at any time in the first 28 days post-transplant. If (1) after achievement of an absolute neutrophil count (ANC) &gt;=500/mm3, the ANC declines to &lt;500/mm3 for more than 3 consecutive days in the absence of relapse, or, (2) there is absence of donor cells in the marrow and/or blood as demonstrated by chimerism assay in the absence of relapse, a diagnosis of secondary graft failure is made. The patient is not evaluable for graft failure or rejection if recurrence of host MDS is detected concurrently.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-transplant severe morbidity and mortality</measure>
    <time_frame>2 years post-transplant</time_frame>
    <description>The occurrence of severe post-transplant regimen-related severe morbidity (grade IV toxicity) and/or mortality will be the second endpoint of this study. In the context of the agents or agent-combination used for cytoreduction used, particular attention will be given to toxicity involving (1) the liver, (2) the lungs, (3) the oral mucosa and gastrointestinal tract, and (4) the central nervous system.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Graft Versus Host Disease</measure>
    <time_frame>One year</time_frame>
    <description>Patients will be observed for acute and/or chronic graft versus host disease (GvHD). Standard clinical criteria for the grading of acute and chronic GvHD will be done according to IBMTR guidelines.</description>
  </other_outcome>
  <other_outcome>
    <measure>Leukemic Relapse</measure>
    <time_frame>5 years</time_frame>
    <description>For patients with MDS or AML, relapse will be analyzed as to type and genetic origin of the MDS/leukemic cells.</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary malignancies</measure>
    <time_frame>5 years</time_frame>
    <description>Patients will be followed for 5 years through annual contact with their treatment center in order to track the risk of developing a secondary malignancy.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Fanconi Anemia</condition>
  <condition>Severe Marrow Failure</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <condition>Acute Myelogenous Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Arm A: Good Risk Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 18 years old or younger with marrow aplasia or single lineage cytopenias will be receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days), as used in our most current study that led to &gt; 90% survival rates . Busulfan pharmacokinetics will not be used. All patients will receive rabbit ATG (4 doses x 4 days) prior to and granulocyte-colony stimulating factor (G-CSF) after transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells for all patients will be peripheral blood stem cells mobilized by treatment of the donor with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). Enrollment on this arm will include up to 50 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Intermediate Risk Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 18 years old or younger with MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). Busulfan pharmacokinetics will be used in this arm, as the dose of busulfan is higher. All patients will receive rabbit ATG (thymoglobulin) (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for prophylaxis against GVHD. The source of the stem cells for all patients will be peripheral blood stem cells induced and mobilized by treatment of the donor. T-cell will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
The maximum number of patients enrolled in this arm will be 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: High Risk Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 19 years old or older with marrow aplasia or MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). In this study, we will test whether outcomes can be improved, yet engraftment maintained, with a slightly reduced dose of busulfan. Patients will receive rabbit ATG (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells will be peripheral blood stem cells collected from donors treated with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). The maximum number of patients enrolled will be 10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).
A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.
A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity.</description>
    <arm_group_label>Arm A: Good Risk Patients</arm_group_label>
    <arm_group_label>Arm B: Intermediate Risk Patients</arm_group_label>
    <arm_group_label>Arm C: High Risk Patients</arm_group_label>
    <other_name>Myleran</other_name>
    <other_name>Busulfex IV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.</description>
    <arm_group_label>Arm A: Good Risk Patients</arm_group_label>
    <arm_group_label>Arm B: Intermediate Risk Patients</arm_group_label>
    <arm_group_label>Arm C: High Risk Patients</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.</description>
    <arm_group_label>Arm A: Good Risk Patients</arm_group_label>
    <arm_group_label>Arm B: Intermediate Risk Patients</arm_group_label>
    <arm_group_label>Arm C: High Risk Patients</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rabbit ATG</intervention_name>
    <description>Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.</description>
    <arm_group_label>Arm A: Good Risk Patients</arm_group_label>
    <arm_group_label>Arm B: Intermediate Risk Patients</arm_group_label>
    <arm_group_label>Arm C: High Risk Patients</arm_group_label>
    <other_name>thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>All patients will also receive G-CSF post-transplant to foster engraftment.</description>
    <arm_group_label>Arm A: Good Risk Patients</arm_group_label>
    <arm_group_label>Arm B: Intermediate Risk Patients</arm_group_label>
    <arm_group_label>Arm C: High Risk Patients</arm_group_label>
    <other_name>Granulocyte colony-stimulating factor</other_name>
    <other_name>filgrastim</other_name>
    <other_name>neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peripheral blood stem cell</intervention_name>
    <description>The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).</description>
    <arm_group_label>Arm A: Good Risk Patients</arm_group_label>
    <arm_group_label>Arm B: Intermediate Risk Patients</arm_group_label>
    <arm_group_label>Arm C: High Risk Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a diagnosis of Fanconi anemia

          -  Patients must have one of the following hematologic diagnoses:

               1. Severe Aplastic Anemia (SAA), with bone marrow cellularity of &lt;25% OR Severe
                  Isolated Single Lineage Cytopenia and at least one of the following features:

                    1. Platelet count &lt;20 x 109/L or platelet transfusion dependence*

                    2. ANC &lt;1000 x 109/L

                    3. Hgb &lt;8 gm/dl or red cell transfusion dependence*

               2. Myelodysplastic Syndrome (MDS) (based on WHO or IPSS Classification

               3. Acute Myelogenous Leukemia (untreated, in remission or with refractory or
                  relapsed disease)

          -  Donors will be either human leukocyte antigen (HLA) compatible unrelated or
             HLA-genotypically matched related donors (no fully matched sibling donor).

          -  Patients and donors may be of either gender or any ethnic background.

          -  Patients must have a Karnofsky adult, or Lansky pediatric performance scale status &gt;
             70%.

          -  Patients must have adequate physical function measured by:

               1. Cardiac: asymptomatic or if symptomatic then 1) left ventricular ejection
                  fraction (LVEF) at rest must be &gt; 50% and must improve with exercise or 2)
                  Shortening Fraction &gt; 29%

               2. Hepatic: &lt; 5 x upper limit of normal (ULN) alanine transaminase (ALT) and &lt; 2.0
                  mg/dl total serum bilirubin.

               3. Renal: serum creatinine &lt;1.5 mg/dl or if serum creatinine is outside the normal
                  range, then CrCl &gt; 50 ml/min/1.73 m2

               4. Pulmonary: asymptomatic or if symptomatic, DLCO &gt; 50% of predicted

          -  Each patient must be willing to participate as a research subject and must sign an
             informed consent form.

          -  Female patients and donors must not be pregnant or breastfeeding at the time of
             signing consent. Women must be willing to undergo a pregnancy test prior to transplant
             and avoid becoming pregnant while on study.

        Exclusion Criteria:

          -  Active CNS leukemia

          -  Female patients who are pregnant (positive serum or urine HCG) or breast-feeding.

          -  Active uncontrolled viral, bacterial or fungal infection

          -  Patient seropositive for HIV-I/II; HTLV -I/II
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parinda Mehta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CCHMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamie Wilhelm</last_name>
    <phone>(513)803-1102</phone>
    <email>Jamie.Wilhelm@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Loveless, RN</last_name>
    <phone>(513)803-7656</phone>
    <email>Sara.Loveless@cchmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Parinda Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Ballard</last_name>
      <phone>206-667-4222</phone>
      <email>sballard@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>K. Scott Baker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>marrow aplasia</keyword>
  <keyword>cytopenia</keyword>
  <keyword>myelodysplasia</keyword>
  <keyword>AML</keyword>
  <keyword>bone marrow transplant</keyword>
  <keyword>cytoreductive regimen</keyword>
  <keyword>T-cell reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

